6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $62M | -$102M | 0.0% | -178.4% | -$140M | — | $112M |
| 2024 | $42M | -$130M | 0.0% | -346.1% | -$132M | — | $70M |
| 2023 | $37M | -$102M | 0.0% | -312.6% | -$120M | — | $66M |
| 2022 | $25M | -$108M | 0.0% | -446.8% | -$117M | — | $60M |
| 2021 | $37M | -$58M | 0.0% | -157.1% | -$61M | — | $143M |
| 2020 | $8M | -$52M | 0.0% | -681.8% | $69M | — | $28M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$46M | — | — | -$44M | — | $158M |
| Dec '25 | $0 | -$39M | — | — | -$30M | — | $112M |
| Sep '25 | $54M | $16M | 0.0% | 26.2% | -$31M | — | $58M |
| Jun '25 | $3M | -$39M | 0.0% | -1287.9% | -$37M | — | $39M |
| Mar '25 | $5M | -$40M | 0.0% | -788.8% | -$42M | — | $58M |
| Dec '24 | $4M | -$38M | 0.0% | -993.7% | -$37M | — | $70M |
| Sep '24 | $12M | -$29M | 0.0% | -283.3% | -$34M | — | $53M |
| Jun '24 | $20M | -$26M | 0.0% | -148.7% | -$24M | — | $52M |
| Mar '24 | $6M | -$38M | 0.0% | -653.0% | -$38M | — | $61M |
| Dec '23 | $5M | -$31M | 0.0% | -644.7% | -$28M | — | $66M |
| Sep '23 | $11M | -$22M | 0.0% | -238.8% | -$31M | — | $59M |
| Jun '23 | $15M | -$21M | 0.0% | -159.2% | -$25M | — | $66M |
| Mar '23 | $6M | -$28M | 0.0% | -525.3% | -$36M | — | $57M |
| Dec '22 | $6M | -$29M | 0.0% | -476.8% | -$29M | — | $60M |
| Sep '22 | $7M | -$29M | 0.0% | -432.4% | -$23M | — | $100M |
| Jun '22 | $6M | -$25M | 0.0% | -436.7% | -$33M | — | $105M |
| Mar '22 | $6M | -$25M | 0.0% | -440.8% | -$31M | — | $100M |
| Dec '21 | $6M | -$22M | 0.0% | -384.6% | -$18M | — | $143M |
| Sep '21 | $7M | -$20M | 0.0% | -288.3% | -$22M | — | $205M |
| Jun '21 | $18M | -$4M | 0.0% | -25.1% | -$8M | — | $582938 |
How the market has priced TNGX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Tango Therapeutics, Inc.'s revenue has grown 52.1% per year. These are computed facts, not advice.
As of FY2025, Tango Therapeutics, Inc. reported — of total debt against $112M of cash.
In FY2025, gross margin was —, operating margin -178.4%, and net margin -162.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.